Ze-Qin Guo

952 total citations
14 papers, 611 citations indexed

About

Ze-Qin Guo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ze-Qin Guo has authored 14 papers receiving a total of 611 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ze-Qin Guo's work include Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (3 papers) and Ferroptosis and cancer prognosis (3 papers). Ze-Qin Guo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (3 papers) and Ferroptosis and cancer prognosis (3 papers). Ze-Qin Guo collaborates with scholars based in China, United States and Germany. Ze-Qin Guo's co-authors include Dehua Wu, Li Liu, Jian Wang, Zhong‐Yi Dong, Jingyuan Sun, Chuanhui Cao, Zhenru Zhu, Xue Bai, Xin-Ran Tang and Xue‐Jun Guo and has published in prestigious journals such as Nature Communications, Cancer Research and Clinical Cancer Research.

In The Last Decade

Ze-Qin Guo

14 papers receiving 606 citations

Peers

Countries citing papers authored by Ze-Qin Guo

Since Specialization

Citations

This map shows the geographic impact of Ze-Qin Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ze-Qin Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ze-Qin Guo more than expected).

Fields of papers citing papers by Ze-Qin Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ze-Qin Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ze-Qin Guo. The network helps show where Ze-Qin Guo may publish in the future.

Co-authorship network of co-authors of Ze-Qin Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Ze-Qin Guo. A scholar is included among the top collaborators of Ze-Qin Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ze-Qin Guo. Ze-Qin Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy 2023 ·Nature Communications ·Xue Bai, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Lijuan Liu, Li Liu, (unknown), Si-Cong Ma, (unknown), Yuan Fang, Xin-Ran Tang, (unknown), Xinghua Pan, Dehua Wu, Zhong‐Yi Dong	35
2	Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation 2023 ·BMC Medicine ·Xue‐Jun Guo, (unknown), (unknown), Yan-Pei Zhang, (unknown), Xue Bai, Jian Wang, Qiang Fu, Ze-Qin Guo, (unknown), Si-Cong Ma, Xin-Ran Tang, Li Liu, Jian Guan, Zhong‐Yi Dong, Dehua Wu	12
3	Targeting NAD+ metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression 2023 ·Hepatology International ·(unknown), (unknown), (unknown), (unknown), Dongyan Zhang, Jingyuan Sun, Ze-Qin Guo, Leyuan Wu, Lushan Xiao, Li Liu	10
4	PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer 2022 ·Cancer Research ·(unknown), Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, (unknown), Li Liu, (unknown), (unknown), (unknown), Xue‐Jun Guo, (unknown), (unknown), Yan Lin, Xinghua Pan, Dehua Wu, Xue Bai, Zhong‐Yi Dong	19
5	Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice 2022 ·BMC Medicine ·Si-Cong Ma, Xue Bai, Xue‐Jun Guo, Li Liu, Lushan Xiao, Yan Lin, (unknown), (unknown), (unknown), (unknown), Qiang Fu, (unknown), Yan-Pei Zhang, (unknown), Ze-Qin Guo, Dehua Wu, Jian‐Guo Zhou, Zhong‐Yi Dong	9
6	De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma 2021 ·Frontiers in Oncology ·Si-Cong Ma, Hongbo Zhu, Jian Wang, Yan-Pei Zhang, Xue‐Jun Guo, (unknown), Ze-Qin Guo, Dehua Wu, Zhong‐Yi Dong, Xue Bai	4
7	Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies 2021 ·OncoImmunology ·Si-Cong Ma, Xin-Ran Tang, (unknown), Xue Bai, Jian‐Guo Zhou, (unknown), Jian Wang, Qiang Fu, Hongbo Zhu, Xue‐Jun Guo, Yan-Pei Zhang, Ze-Qin Guo, Dehua Wu, Zhong‐Yi Dong	14
8	Upregulated long non‑coding RNA LincIN promotes tumor progression via the regulation of nuclear factor 90/microRNA‑7/HOXB13 in esophageal squamous cell carcinoma 2021 ·International Journal of Molecular Medicine ·(unknown), Peitao Zhou, Zhenru Zhu, Ying Wang, Ze-Qin Guo, (unknown), (unknown), Weixi Shen, Dehua Wu	5
9	Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2 2020 ·Journal of Experimental & Clinical Cancer Research ·Dongyan Zhang, (unknown), Xuejing Zou, Yang Song, Wenwen Li, Ze-Qin Guo, Shanshan Liu, Li Liu, Dehua Wu	27
10	Reciprocal regulation of HIF-1α and Uroplakin 1A promotes glycolysis and proliferation in Hepatocellular Carcinoma 2020 ·Journal of Cancer ·Yang Song, Hui Wang, Xuejing Zou, Yaxuan Zhang, Ze-Qin Guo, Li Liu, Dehua Wu, Dongyan Zhang	5
11	UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation 2020 ·Journal of Experimental & Clinical Cancer Research ·Jingyuan Sun, Zhenru Zhu, Wenwen Li, (unknown), Chuanhui Cao, (unknown), Ze-Qin Guo, Li Liu, Dehua Wu	70
12	[Spindle assembly checkpoint complex-related genes TTK and MAD2L1 are over-expressed in lung adenocarcinoma: a big data and bioinformatics analysis]. 2020 ·PubMed ·(unknown), Ze-Qin Guo, (unknown), Yan-Pei Zhang, Yuwen Lu, Dehua Wu, Zhong‐Yi Dong	2
13	ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma 2020 ·Journal for ImmunoTherapy of Cancer ·Hailong Sheng, Yan Huang, (unknown), Zhenru Zhu, (unknown), Peitao Zhou, Ze-Qin Guo, Jian Wang, Hui Wang, Wencong Dai, Wanjun Zhang, Jingyuan Sun, Chuanhui Cao	166
14	Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer 2019 ·Clinical Cancer Research ·Li Liu, Xue Bai, Jian Wang, Xin-Ran Tang, Dehua Wu, Shasha Du, Xiuju Du, Yaowei Zhang, Hongbo Zhu, Yuan Fang, Ze-Qin Guo, Qin Zeng, Xue‐Jun Guo, Zhu Liu, Zhong‐Yi Dong	233

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact